The Vanguard Group, Inc. recently announced the acquisition of new stake in Irobot Corp (NASDAQ:IRBT). The institutional investor has increased its shareholding in the Consumer Cyclical company by 0.68% to 2.88 million shares with purchase of 19346.0 shares. This fresh investment now brings its stake to 10.33% valued currently at $111.4 million. In addition, SSgA Funds Management, Inc. raised its holdings by 24025.0 to 1.13 million shares. And Dimensional Fund Advisors LP has lifted its position by 1.99% or 11188.0 shares – to 0.57 million shares.
Currently, there are 27.42M common shares owned by the public and among those 26.92M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Insiders at the company have transacted a total of 58 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 15 of these insider trades were purchases, accounting for 153,134 shares. Insider sales of the common stock occurred on 43 occasions, with total insider shares sold totaling 66,343 shares.
The top 3 mutual fund holders in Irobot Corp are iShares Core S&P Small Cap ETF, PRIMECAP Odyssey Growth Fund, and Vanguard Total Stock Market ETF. iShares Core S&P Small Cap ETF owns 1.88 million shares of the company’s stock, all valued at over $72.6 million. The company bought an additional 1870.0 shares recently to bring their total holdings to about 6.73% of the shares outstanding. PRIMECAP Odyssey Growth Fund sold 16898.0 shares to see its total holdings shrink to 1.03 million shares valued at over $39.68 million and representing 3.68% of the shares outstanding. Vanguard Total Stock Market ETF bought 2562.0 shares to bring its total holdings to over 0.83 million shares at a value of $32.24 million. Vanguard Total Stock Market ETF now owns shares totaling to 2.99% of the shares outstanding.
However, the script later moved the day high at 19.68, up 6.33%. The company’s stock has a 5-day price change of -38.83% and -48.88% over the past three months. IRBT shares are trading -52.25% year to date (YTD), with the 12-month market performance down to -59.72% lower. It has a 12-month low price of $15.77 and touched a high of $51.49 over the same period. IRBT has an average intraday trading volume of 1.40 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -44.55%, -46.03%, and -51.34% respectively.
Institutional ownership of Irobot Corp (NASDAQ: IRBT) shares accounts for 80.97% of the company’s 27.42M shares outstanding. Mutual fund holders own 33.45%, while other institutional holders and individual stakeholders account for 48.67% and 15.68% respectively.
It has a market capitalization of $515.04M and a beta (3y monthly) value of 1.02. The earnings-per-share (ttm) stands at -$11.81. Price movements for the stock have been influenced by the stock’s volatility, which stands at 13.60% over the week and 6.43% over the month.
Analysts forecast that Irobot Corp (IRBT) will achieve an EPS of -$1.83 for the current quarter, -$1.06 for the next quarter and -$3.98 for 2024. The lowest estimate earnings-per-share for the quarter is -$2.42 while analysts give the company a high EPS estimate of -$1.24. Comparatively, EPS for the current quarter was -$1.52 a year ago. Earnings per share for the fiscal year are expected to decrease by -78.88%, and 48.67% over the next financial year.
Looking at the support for the IRBT, a number of firms have released research notes about the stock. JP Morgan stated their Underweight rating for the stock in a research note on May 06, 2022, with the firm’s price target at $65-$45.
